申请人:E. R. Squibb & Sons, Inc.
公开号:US05294722A1
公开(公告)日:1994-03-15
Imidazoles of the formula ##STR1## are prepared by treating a ketone ##STR2## with a nitrogenic acid, nitrite or nitrate in the presence of an acid to form a hydroxynitrile ##STR3## which is treated with R.sup.2 --CHO and an ammonium to form an N-hydroxyimidazole ##STR4## which is reduced in the presence of a buffer. In these compounds, R.sup.1 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; R.sup.2 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, or --(CH.sub.2).sub.m Z(CH.sub.2).sub.n R.sup.3, each of which is optionally substituted with F or --CO.sub.2 R.sup.1 ; or aryl or aralkyl, each of which is optionally substituted with 1 or 2 groups selected from halogen, lower alkoxy, lower alkyl, or nitro; R.sup.3 is hydrogen, alkyl, cycloalkyl, lower alkenyl, or lower alkynyl; and the remaining symbols are as defined in the specification.
式子##STR1##的咪唑类化合物是通过在酸的存在下,用含氮酸、亚硝酸盐或硝酸盐处理酮##STR2##,形成羟基腈##STR3##,然后用R.sup.2 --CHO和铵盐处理,形成N-羟基咪唑##STR4##,在缓冲剂的存在下还原而制备的。在这些化合物中,R.sup.1是氢、烷基、卤代烷基、环烷基、环烷基烷基、芳基或芳基烷基;R.sup.2是烷基、烯基、炔基、环烷基、环烷基烷基、环烷基烯基、环烷基炔基或--(CH.sub.2).sub.m Z(CH.sub.2).sub.n R.sup.3,其中每个都可以用F或--CO.sub.2 R.sup.1替换;或芳基或芳基烷基,每个都可以用卤素、低烷氧基、低烷基或硝基中选择1或2个基进行置换;R.sup.3是氢、烷基、环烷基、低烯基或低炔基;其余符号如说明书中所定义。